PFIZER INC.

Juvenescence Limited has acquired Ro5 Inc., an AI drug discovery company with a proprietary Biomedical Knowledge Graph comprising over 85 million nodes and 400 million relationships.

Biodexa Pharmaceuticals has enrolled the first patient in a Phase 2 study evaluating tolimidone, a selective Lyn kinase activator, for Type 1 diabetes treatment.

Bristol Myers Squibb will pay BioNTech $1.5 billion upfront plus $2 billion in anniversary payments through 2028 for a 50% partnership in BNT327, a bispecific antibody targeting both PD-L1 and VEGF proteins.

Valneva's VLA15 represents the world's leading Lyme disease vaccine candidate and is currently being evaluated in a pivotal Phase 3 trial with partner Pfizer.

Acadia Pharmaceuticals has appointed Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise, bringing over 20 years of pharmaceutical industry experience.

GlycoEra raised $130 million in Series B funding led by Novo Holdings to advance its lead protein degrader GE8820 into first-in-human clinical trials.

The antibody-drug conjugate (ADC) market in non-small-cell lung cancer is projected to grow at a 6.8% CAGR across seven major markets and exceed $3.9 billion by 2032.

The 15th World ADC San Diego conference (November 4-7, 2024) represents the industry's largest and most comprehensive ADC-focused forum, featuring 120+ speakers across six development tracks.

Pfizer has completed a record-breaking $6 billion acquisition deal with Chinese biopharmaceutical company 3SBio, energizing China's innovative drug industry and potentially driving further valuations upward.

The US Court of Appeals for the Federal Circuit affirmed the Patent Trial and Appeal Board's decisions invalidating uniQure's patents covering Hemgenix, a gene therapy for hemophilia B treatment.